Abstract #5564

Characterization of Gadolinium Deposition in the Brain Manifest as T2-hypointensity and T1-hyperintensity Associated with Repeat Monthly Triple-Dose Gadopentetate Dimeglumine Administration for 2 years in the BECOME Trial

Paul Allen DiCamillo^1,2, Michael Benjamin Shvarts^1,2, Ravi Bhasker Patel^2,3,4, Jhimli Mitra³, Pallavi Tiwari³, Stuart D Cook⁵, Diego Cadavid⁵, Robert T Naismith⁶, Samantha Lancia⁶, and Leo J Wolansky^1,2

¹Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States, ²Case Western Reserve University School of Medicine, Cleveland, OH, United States, ³Department of Biomedical Engineering, Case Western Reserve University School of Medicine, Cleveland, OH, United States, ⁴Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States, ⁵Department of Neurology, Rutgers-New Jersey Medical School, Newark, NJ, United States, ⁶Neurology, Washington University School of Medicine, St. Louis, MO, United States

We characterize the brain parenchymal deposition of Gadolinium (Gd) in the dentate nucleus (DN) and globus pallidus (GP) in a cohort of 16 subjects with multiple sclerosis (MS), each of whom had systematically received one year of serial monthly triple dose Gd (3-dose Gd) and optional additional monthly exposure for a second year. Progressive increase in T1 signal and decrease in T2 signal is found in both the dentate nucleus and globus pallidus.

This abstract and the presentation materials are available to members only; a login is required.

Join Here